PREGNANCY PLANNING AND PHARMACOTHERAPY FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Maria Nowakowska; Jakub Senko; Zofia Suchanek; Kornelia Tyczka; Marcin Szczepanik; Joanna Kulpa

doi:10.31435/ijitss.3(51).2026.6319

Authors

Maria Nowakowska University Teaching Hospital No. 1 of the Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0007-2321-0464
Jakub Senko Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0006-2878-5737
Zofia Suchanek Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0009-0003-6911-230X
Kornelia Tyczka Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland
Marcin Szczepanik Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0009-0004-0475-6187
Joanna Kulpa Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0007-7057-6282

DOI:

https://doi.org/10.31435/ijitss.3(51).2026.6319

Keywords:

Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Antiphospholipid Syndrome (APS), Pregnancy, Antiphospholipid Antibodies

Abstract

Background: SLE is an intriguing topic of research, given the severity of the disease and the impact in can have on a pregnant body is why this analysis and future research can help to better the understanding on how to improve patients' healthcare.

Aim: This narrative review analysis the current available treatment methods for patients with SLE and the risks of SLE and pregnancy.

Material and methods: A search of relevant research databases was conducted to identify eligible papers.

Results: More research needs to be conducted to improve the understanding and improve SLE treatment in pregnant patients.

Conclusions: SLE is a complex condition the variety of symptoms and risks factors in pregnancy are why new methods of treatment, improved specialist care and novel therapies are vital in its treatment.

References

Akhil, A., Bansal, R., Anupam, K., Tandon, A., & Bhatnagar, A. (2023). Systemic lupus erythematosus: Latest insight into etiopathogenesis. Rheumatology International, 43(8), 1381–1393.

Tian, J., Zhang, D., Yao, X., Huang, Y., & Lu, Q. (2023). Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351–356.

Weckerle, C. E., & Niewold, T. B. (2011). The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies. Clinical Reviews in Allergy & Immunology, 40(1), 42–49.

Dao, K. H., & Bermas, B. L. (2022). Systemic lupus erythematosus management in pregnancy. International Journal of Women’s Health, 14, 199–211.

Wang, X., Li, J., Liang, Q., Ni, X., Zhao, R., Fu, T., et al. (2022). Reproductive concerns and contributing factors in women of childbearing age with systemic lupus erythematosus. Clinical Rheumatology, 41(8), 2383–2391.

Geva, E., Lerner-Geva, L., Burke, M., Vardinon, N., Lessing, J. B., & Amit, A. (2004). Undiagnosed systemic lupus erythematosus in a cohort of infertile women. American Journal of Reproductive Immunology, 51(5), 336–340.

Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., et al. (2016). The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases, 75(5), 795–810.

Andreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., et al. (2017). EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy, and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the Rheumatic Diseases, 76(3), 476–485.

Buyon, J. P., Kim, M. Y., Guerra, M. M., Laskin, C. A., Petri, M., Lockshin, M. D., et al. (2015). Predictors of pregnancy outcomes in patients with lupus: A cohort study. Annals of Internal Medicine, 163(3), 153–163.

Kwok, L. W., Tam, L. S., Zhu, T., Leung, Y. Y., & Li, E. (2011). Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus, 20(8), 829–836.

Yang, H., Liu, H., Xu, D., Zhao, L., Wang, Q., Leng, X., et al. (2014). Pregnancy-related systemic lupus erythematosus: Clinical features, outcome, and risk factors of disease flares—A case-control study. PLOS ONE, 9(8), e104375.

Cabiddu, G., Castellino, S., Gernone, G., Santoro, D., Moroni, G., Giannattasio, M., et al. (2016). A best practice position statement on pregnancy in chronic kidney disease: The Italian Study Group on Kidney and Pregnancy. Journal of Nephrology, 29(3), 277–303.

Bramham, K., Hunt, B. J., Bewley, S., Germain, S., Calatayud, I., Khamashta, M. A., et al. (2011). Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. The Journal of Rheumatology, 38(9), 1906–1913.

Moroni, G., Quaglini, S., Gallelli, B., Banfi, G., Messa, P., & Ponticelli, C. (2007). The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrology Dialysis Transplantation, 22(9), 2531–2539.

Brucato, A., Cimaz, R., Caporali, R., Ramoni, V., & Buyon, J. (2011). Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clinical Reviews in Allergy & Immunology, 40(1), 27–41.

Izmirly, P. M., Costedoat-Chalumeau, N., Pisoni, C. N., Khamashta, M. A., Kim, M. Y., Saxena, A., et al. (2012). Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation, 126(1), 76–82.

Miyakis, S., Lockshin, M. D., Atsumi, T., Branch, D. W., Brey, R. L., Cervera, R., et al. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4(2), 295–306.

Lockshin, M. D., Kim, M., Laskin, C. A., Guerra, M., Branch, D. W., Merrill, J., et al. (2012). Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis & Rheumatism, 64(7), 2311–2318.

Roberge, S., Demers, S., & Bujold, E. (2014). Low-dose aspirin for prevention of morbidity and mortality from preeclampsia. Annals of Internal Medicine, 161(8), 613.

van Vollenhoven, R. F., Mosca, M., Bertsias, G., Isenberg, D., Kuhn, A., Lerstrøm, K., et al. (2014). Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Annals of the Rheumatic Diseases, 73(6), 958–967.

Wind, M., Fierro, J. J., Bloemenkamp, K. W. M., de Leeuw, K., Lely, A. T., Limper, M., et al. (2024). Pregnancy outcome predictors in systemic lupus erythematosus: A systematic review and meta-analysis. The Lancet Rheumatology, 6(10), e667–e683.

Tani, C., Zucchi, D., Haase, I., Larosa, M., Crisafulli, F., Strigini, F. A. L., et al. (2021). Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. Rheumatology, 60(12), 5610–5619.

Wyszynski, D. F. (2026). Systemic lupus erythematosus and pregnancy: A comprehensive clinical review of maternal, fetal, and treatment considerations. Advances in Rheumatology.

Jiang, Y., Tao, M., Chen, J., Luo, L., You, Q., Wu, H., et al. (2024). Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: A narrative review with emphasis on efficacy and safety. European Journal of Obstetrics & Gynecology and Reproductive Biology, 294, 148–155.

Petri, M. (2020). Pregnancy and systemic lupus erythematosus. Best Practice & Research Clinical Obstetrics & Gynaecology, 64, 24–30.

Do, S. C., & Druzin, M. L. (2019). Systemic lupus erythematosus in pregnancy: High risk, high reward. Current Opinion in Obstetrics & Gynecology, 31(2), 120–126.

Eudy, A. M., Siega-Riz, A. M., Engel, S. M., Franceschini, N., Howard, A. G., Clowse, M. E. B., et al. (2018). Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 77(6), 855–860.

Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010). Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Annals of the Rheumatic Diseases, 69(1), 20–28.

de Jesus, G. R., Mendoza-Pinto, C., de Jesus, N. R., Dos Santos, F. C., Klumb, E. M., Carrasco, M. G., et al. (2015). Understanding and managing pregnancy in patients with lupus. Autoimmune Diseases, 2015, 943490.

Mitchell, K., Kaul, M., & Clowse, M. E. (2010). The management of rheumatic diseases in pregnancy. Scandinavian Journal of Rheumatology, 39(2), 99–108.

Gamba, A., Zen, M., Depascale, R., Calligaro, A., Gatto, M., Iaccarino, L., et al. (2024). Modern management of pregnancy in systemic lupus erythematosus: From prenatal counseling to postpartum support. Journal of Clinical Medicine, 13(12).

Silver, R., Craigo, S., Porter, F., Osmundson, S. S., Kuller, J. A., Norton, M. E., et al. (2023). Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. American Journal of Obstetrics and Gynecology, 228(3), B41–B60.

Alothman, R., Yeung, J., Waterman, E., Lepik, C., & Amiri, N. (2023). Leflunomide exposure through the second trimester of pregnancy: A case report. Birth Defects Research, 115(16), 1566–1569.

Fernandes, M., Bernardino, V., Taulaigo, A., Fernandes, J., Lladó, A., & Fátima, S. (2021). Systemic lupus erythematosus pregnancy. In R. Hamdy (Ed.), Lupus—Need to know. IntechOpen.

Saleh, Z. F., Somers, E. C., Romero, V. C., & Marder, W. (2026). Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies. American Journal of Obstetrics and Gynecology, 234(1), 7–20.

He, W. R., & Wei, H. (2020). Maternal and fetal complications associated with systemic lupus erythematosus: An updated meta-analysis of the most recent studies (2017–2019). Medicine, 99(16), e19797.

Yue, C., Huang, W., Han, J., Zhang, Y., Zeng, X., Gao, R., et al. (2026). Pregnancy and assisted reproductive outcomes in women with systemic lupus erythematosus, Sjögren syndrome, and antiphospholipid syndrome: An umbrella review. Journal of Clinical Medicine, 15(7).

Wu, J., Zhang, W. H., Ma, J., Bao, C., Liu, J., & Di, W. (2019). Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: A retrospective cohort study. BMJ Open, 9(2), e023849.

Mankee, A., Petri, M., & Magder, L. S. (2015). Lupus anticoagulant, disease activity, and low complement in the first trimester are predictive of pregnancy loss. Lupus Science & Medicine, 2(1), e000095.

Dong, Y., Yuan, F., Dai, Z., Wang, Z., Zhu, Y., & Wang, B. (2020). Preeclampsia in systemic lupus erythematosus pregnancy: A systematic review and meta-analysis. Clinical Rheumatology, 39(2), 319–325.

Miller, E. C., Wilczek, A., Bello, N. A., Tom, S., Wapner, R., & Suh, Y. (2022). Pregnancy, preeclampsia, and maternal aging: From epidemiology to functional genomics. Ageing Research Reviews, 73, 101535.

Abdwani, R., Al Shaqsi, L., & Al-Zakwani, I. (2018). Neonatal and obstetrical outcomes of pregnancies in systemic lupus erythematosus. Oman Medical Journal, 33(1), 15–21.

Levesque, K., Morel, N., Maltret, A., Baron, G., Masseau, A., Orquevaux, P., et al. (2015). Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmunity Reviews, 14(12), 1154–1160.

Huang, Y., Deng, J., Liu, J., Yang, F., & He, Y. (2024). Autoimmune congenital heart block: A case report and review of the literature related to pathogenesis and pregnancy management. Arthritis Research & Therapy, 26(1), 8.